leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Vaccine Manufacturing Technology and Services: World Market 2011-2021

Vaccine Manufacturing Technology and Services: World Market 2011-2021

  • Publication date: 06/10/2011
  • Number of Pages: 115
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

What does the future hold for the vaccine manufacturing industry and market? Visiongain's report shows you potential revenues and trends to 2021. Find opportunities and prospects.

Do you want to know where the market is heading? Discover activities shaping the vaccines market and the outsourcing of vaccine manufacturing for human healthcare. Through our research and analysis we aim to save you time and help in your decisions.

Vaccine manufacturing will become more important this decade. Our study discusses activities of GSK, Sanofi, Merck & Co., Novartis, Pfizer and others. See how changes in the pharma industry affect production, outsourcing and contract service providers (CMOs).

There, you find potential revenues for vaccines at total world and submarket levels to 2021. You also find revenue predictions for contract vaccine manufacturing. You receive forecasts of vaccine volumes (by dose) too, including geographical production data.

What are the prospects for the outsourcing market? Assess SynCo Bio Partners, Baxter BioPharma Solutions and Meridian Life Sciences. Find information you need. Markets and R&D for vaccines remain strong, with opportunities for vaccine manufacturing specialists.

We discuss egg-based systems, mammalian cell lines, avian cell lines, plant-based systems, expression systems, vectors, adjuvants, delivery systems and formulations. You see the potential for technologies and services for vaccine production from 2011 onwards.

Our report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. You can find answers now in our work.

Forecasts, market shares, commercial trends, discussions and interviews

In our report you find forecasts of revenues and volumes, as well as market shares. You also receive qualitative analyses, opinions from industry and a review of companies. Discover 42 tables and charts and two research interviews.

Advantages of Vaccine Manufacturing Technology and Services: World Market 2011-2021 for your work

Our report gives you the following advantages in particular:
• Discover revenue forecasts to 2021 for the world vaccines market and its main submarkets, finding growth potential
• See revenue forecasting to 2021 for the outsourced production of vaccines
• Receive forecasts of production volumes (by dose) to 2021 for the world, North America, France, Germany, Belgium, Switzerland and Austria
• Find trends in vaccine production technologies and services
• Review leading companies in vaccine manufacturing, finding activities and outlooks
• Assess competition and opportunities that will influence revenues
• See what will stimulate and restrain the industry and market from 2011
• View opinions from our survey, reading interviews.

There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions on vaccine production, helping you to stay ahead.

Gain industry and market analysis now for vaccine production

Our report is for everybody needing industry and market analysis for vaccine production. Find trends and answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary
1.1 Overview
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods

2. Introduction to Vaccines
2.1 Basics of Vaccines
2.2 Utility of Vaccines
2.3 Formulation of Vaccines
2.4 Types of Vaccines
2.4.1 Live, Attenuated Vaccines
2.4.2 Recombinant Live Vaccines
2.4.3 Inactivated Vaccines
2.4.4 Toxoid Vaccines
2.4.5 Subunit Vaccines
2.4.6 Conjugate Vaccines
2.4.7 Recombinant Subunit Vaccines
2.4.8 DNA Vaccines
2.4.9 Recombinant Vector Vaccines
2.5 Diseases Preventable with Vaccines
2.5.1 Chickenpox and Shingles
2.5.2 Cholera
2.5.3 Diphtheria
2.5.4 Haemophilus Influenza Type B (Hib) Diseases
2.5.5 Hepatitis A
2.5.6 Hepatitis B
2.5.7 Human Papillomavirus (HPV) - Cervical Cancer
2.5.8 Influenza
2.5.8.1 Seasonal Influenza
2.5.8.2 Pandemic Influenza
2.5.8.3 Influenza Vaccination
2.5.9 Japanese Encephalitis
2.5.10 Measles
2.5.11 Meningococcal Diseases (Neisseria Meningitidis)
2.5.12 Mumps
2.5.13 Pertussis
2.5.14 Polio
2.5.15 Rabies
2.5.16 Rotavirus Infections
2.5.17 Rubella
2.5.18 Streptococcus Pneumoniae Infections
2.5.19 Tetanus
2.5.20 Tuberculosis
2.6 Vaccine Manufacture within the Biopharmaceutical Industry
2.6.1 Introduction
2.6.2 GlaxoSmithKline
2.6.2.1 Havrix
2.6.2.2 Engerix-B
2.6.2.3 Twinrix/Ambirix
2.6.3 Merck & Co.
2.6.3.1 Gardasil
2.6.4 Novartis
2.6.4.1 Optaflu (Novartis)
2.6.4.2 Pre-Pandemic Vaccines (Novartis)
2.6.5 Sanofi Pasteur
2.6.5.1 Sanofi's H5N1 Influenza Vaccine Programme
2.6.6 Wyeth (Pfizer)
2.6.6.1 Prevnar/Prevenar (Wyeth)

3. Summary of the Global Vaccine Manufacturing Market, 2011-2021
3.1 Overview of the Global Vaccine Manufacturing Market, 2011-2021
3.2 Novel Technologies for Vaccine Manufacturing
3.3 New Substrates for Vaccine Manufacturing
3.3.1 Shift from Egg-Based Manufacturing to Cell-Based Manufacturing Technology
3.3.2 Cell-Based Techniques Clearly Have Advantages
3.3.3 Mammalian Cell Lines
3.3.3.1 MCDK (Madin Darby Canine Kidney Cells)
3.3.3.2 Vero Cells
3.3.3.3 PerC6 Cells
3.3.4 Avian-Derived Cell Lines
3.3.4.1 EB66 Stem Cell Technology: Vivalis
3.3.5 Plant-Based Vaccines
3.3.5.1 Medicago's Proficia VLP Vaccine Technology
3.3.6 Insect Egg-Based Production Systems
3.3.6.1 Novavax
3.3.6.2 Protein Sciences Corporation (PSC)
3.4 Next-Generation Expression Systems and Vectors: Increasing Production Yield
3.4.1 AdVac Technology: Crucell
3.4.2 AdCEV Vectors: AfriVax
3.4.3 Pfenex Expression Technology: Pfenex

4. The Global Vaccine Manufacturing Market, 2011-2021
4.1 The Global Vaccines Market, 2010
4.1.1 Vaccine Types
4.1.2 Leading Vaccine Types by Revenue
4.1.3 Leading Vaccine Manufacturers
4.2 Global Vaccines Market Forecasts, 2011-2021
4.2.1 Forecasts for the Global Vaccines Market, 2010-2015
4.2.2 Forecasts for the Global Vaccines Market, 2016-2021
4.3 Fastest Growing Types of Vaccines, 2011-2021
4.4 Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing
4.5 Global Market for the Manufacture of Vaccines, 2011-2021
4.5.1 Vaccine Manufacturing Market by Volume, 2010
4.5.2 Vaccine Manufacturing Market by Volume, 2010-2021
4.6 Leading National Markets for Vaccine Manufacturing, 2011-2021
4.6.1 Leading Vaccine Manufacturing Destinations, 2010
4.6.2 Leading Vaccine Manufacturing Destinations, 2010-2015
4.6.3 Leading Vaccine Manufacturing Destinations, 2016-2021
4.6.4 Vaccine Production in Developing Countries
4.6.4.1 Promoting Vaccine Production in Developing Countries

5. Outsourcing Vaccine Manufacturing, 2011-2021
5.1 The Challenges in Outsourcing
5.2 Contract Manufacturing Market for Vaccines, 2010-2021
5.2.1 Market Size for Contract Manufacturing of Vaccines, 2010
5.2.2 Forecast for the Vaccine Manufacturing Market, 2010-2015
5.2.3 Forecast for the Vaccine Contract Manufacturing Market, 2016-2021
5.3 Activities Typically Outsourced
5.3.1 Leading Vaccine Contract Manufacturing Organisations
5.3.1.1 SynCo Bio Partners
5.3.1.2 Baxter BioPharma Solutions
5.3.1.3 Meridian Life Sciences
5.4 Changes in the Vaccine Market to Drive Contract Manufacturing
5.5 Trends in Therapeutic Discovery and Manufacturing
5.6 Long-Term Contracts, Strategic Outsourcing and Alliances with Academic Laboratories
5.6.1 Strategic Alliances with Non-Profit and Academic Laboratories

6. Factors Affecting the Vaccine Manufacturing Market
6.1 SWOT Analysis Table
6.2 The Strengths of the Global Vaccine Manufacturing Market
6.2.1 Vaccines are Important Agents for Disease Control
6.2.2 New Vaccine Technologies
6.2.2.1 Vaccine Manufacturers are Expanding the Scope of Vaccines
6.2.2.2 New Types of Vaccines
6.2.2.3 New Adjuvants for Vaccines
6.2.2.4 New Vaccine Delivery Mechanisms and Formulations
6.2.2.5 Other Developments in Vaccine Technology
6.2.3 New High-Margin Vaccines
6.2.4 Vaccines Will Not Suffer from Significant Generic Competition
6.2.5 Personalised Vaccines
6.3 The Weaknesses of the Global Vaccine Manufacturing Market
6.3.1 It Remains Difficult to Forecast the Demand for Vaccines
6.3.2 High Costs and Complex Manufacturing Processes
6.3.3 Limitations of the Production Facility: Difficult to Change Over to a Different Product
6.4 Opportunities for Vaccine Manufacturers and Manufacturing Countries
6.4.1 China, India and Brazil Will Become Hubs for Manufacturing Paediatric Vaccines
6.4.2 Vaccines for Diseases Currently Without a Vaccine
6.4.3 Biodefence: Vaccines Against Bioterrorism
6.4.4 Pandemic-Preparedness
6.4.5 Changing World Demographics
6.5 Threats
6.5.1 Consolidation Among Vaccine Manufacturers
6.5.2 Vaccines in the Developing World
6.5.2.1 Vaccine Distribution Networks
6.5.2.2 Vaccine Provision in Developing Countries

7. Research Interviews
7.1 Mr Patrick Lucy, Vice President, Business Development, Pfenex
7.1.1 Pfenex Technology
7.1.2 The Service Offering of Pfenex
7.1.3 The Current State of Vaccine Manufacturing
7.1.4 Novel Platforms Driving the Vaccines Market
7.2 Dr Roger Lias, President & Group Commercial Director, Eden Biodesign
7.2.1 Contract Manufacturing Market
7.2.2 Future Growth Prospects for Vaccines Contract Manufacturing
7.2.3 Capabilities of Eden Biodesign
7.2.4 Industry Drivers

8. Conclusions
8.1 Vaccine Manufacturing Market Will Grow
8.2 Drivers for Change in Vaccines Manufacturing
8.2.1 Market Forces
8.2.2 Technological Developments
8.2.3 Social Forces
8.2.4 Economic Forces
8.3 Trend Towards Greater Use of Disposable Single-Use Systems
8.4 Developing Countries Will Need the Most Vaccines Developed
8.4.1 Africa and Asia Will See Demand for Vaccines Rise
8.4.2 Drug and Vaccine Safety Still a Concern in Developing Countries
8.5 The Balance of Power within the Vaccines Market Will Shift
8.6 Public Misunderstanding of the Dangers of Vaccination Will Continue to Threaten Market Growth
8.7 Generic Vaccines are Unlikely to Threaten Sales of Multi-National Vaccine Manufacturers
8.7.1 Novel Vaccine Technologies Will Drive Growth in this Market

List of Tables
Table 2.1 Vaccine-Preventable Diseases: Statistics from Recent Years
Table 2.2 Influenza Virus Types, 2011
Table 3.1 Revenues ($bn) for the Global Vaccines Market, 2011-2021
Table 3.2 Vaccine Development Pipeline using Protein Sciences Corporation's BEVS Vaccine Technology, 2011
Table 3.3 Vaccine Development Pipeline using Crucell's AdVac Technology, 2011
Table 4.1 Definition of Vaccine Types, 2011
Table 4.2 Revenues ($bn) and Market Shares (%) of Vaccines by Type, 2010
Table 4.3 Vaccine Sales ($bn) and Market Shares (%) by Manufacturer, 2010
Table 4.4 Global Vaccines Market Forecast ($bn), 2010-2015
Table 4.5 Global Vaccines Market Forecast ($bn), 2016-2021
Table 4.6 Global Vaccines Market Forecasts ($bn) by Vaccine Type, 2010-2021
Table 4.7 Global Vaccine Production (bn doses) and Market Shares (%), 2010
Table 4.8 Global Vaccine Production (bn doses) Forecast, 2010-2015
Table 4.9 Global Vaccine Production (bn doses) Forecast, 2016-2021
Table 4.10 Vaccine Production (bn doses) in Leading Producing Countries, 2010
Table 4.11 Vaccine Production (bn doses) in Leading Producing Countries, 2010-2015
Table 4.12 Vaccine Production (bn doses) in Leading Producing Countries, 2016-2021
Table 4.13 Prominent Vaccine Manufacturers in Developing Countries, 2011
Table 5.1 Share ($m) of Vaccines in Biologics Contract Manufacturing, 2010
Table 5.2 Vaccines Contract Manufacturing Revenues ($m), 2010-2015
Table 5.3 Vaccines Contract Manufacturing Revenues ($m), 2016-2021
Table 5.4 Prominent Contract Manufacturing Organisations, 2011
Table 6.1 SWOT Analysis for the Global Vaccine Manufacturing Sector, 2011
Table 8.1 Benefits and Drawbacks of Using Disposable Technology for Vaccine Production, 2011
Table 8.2 Companies Providing Disposable Biomanufacturing Platforms/Systems, 2011

List of Figures
Figure 3.1 Revenues ($bn) for the Global Vaccines Market, 2011-2021
Figure 3.2 Influenza Vaccine Production Using a Cell-Based Manufacturing Method, 2011
Figure 3.3 Novavax' Insect Egg-Based Vaccine Production Process, 2011
Figure 4.1 Market Shares (%) of Vaccines by Type, 2010
Figure 4.2 Vaccine Market Shares (%) by Manufacturer, 2010
Figure 4.3 Global Vaccines Market Forecast ($bn), 2010-2015
Figure 4.4 Global Vaccines Market Forecast ($bn), 2016-2021
Figure 4.5 Global Vaccines Market Revenues ($bn) by Vaccine Type, 2010-2021
Figure 4.6 Percentage Share (%) by Volume of the Global Vaccines Market, 2010
Figure 4.7 Global Vaccine Production (bn doses), 2010-2015
Figure 4.8 Global Vaccine Production (bn doses), 2016-2021
Figure 4.9 Regional Shares (%) of Global Vaccine Production, 2010
Figure 4.10 Vaccine Production (bn doses) in Leading Producing Countries, 2010-2015
Figure 4.11 Vaccine Production (bn doses) in Leading Producing Countries, 2016-2021
Figure 5.1 Market Share (%) of Vaccines in Biologics Contract Manufacturing, 2010
Figure 5.2 Vaccines Contract Manufacturing Revenues ($m), 2010-2015
Figure 5.3 Vaccines Contract Manufacturing Revenues ($m), 2016-2021 

Companies Listed

AAI Pharma Services Corp.
A-Bio Pharma Pte
Acambis
ADImmune
Advanced Bioscience Laboratories
AfriVax
Alpha Biologics
Althea Technologies
Angel Biotechnology Holdings
ANVISA
Artelis
Astellas
AstraZeneca
ATMI LifeSciences
Bavarian Nordic
Baxter BioPharma Solutions
Baxter International
Beijing Hau-er-dun Biotech Co.
Beijing Tiantan Biological Products Co.
Bharat Biotech International
Bill and Melinda Gates Foundation
Biogen
Biogen Idec
Bio Farma
Biological E
Bio-Manguinhos
Biomay
Biomed Pvt.
Biomedical Advanced Research and Development Authority (BARDA)
BioNet-Asia Co.
BioProperties Pty.
Biovian
Birmex
Cantacuzino Institute
Catalent Pharma Solutions
Cellexus
Central Research Institute
Charles River Biopharmaceutical Services
Changchun BCHT Pharmaceutical Co.
Changchun Institute of Biological Products
Chengdu Institute of Biological Products
China National Biotec Group
Chiron
Chongqing Jianchen Bioengineering Co.
Chongqing Kangwei Biological Co.
Cognate Bioservices
Cytovance Biologics
Crucell
CSL
Daiichi-Sankyo
Dalian Hissen Bio-pharm Inc.
Dalian Jingang Andi Bio-products Co.
Dalian Jingang Biological Products Co.
Defense Advanced Research Projects Agency (DARPA)
Department of Health and Human Services (US HHS)
Diosynth Biotechnology
DSM Biologics
Eden Biodesign
Eurogentic Biologics
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
European Vaccine Manufacturers (EVM)
Finlay Institute
Florida Biologix
Formatech
GAVI Alliance
GE Healthcare
GlaxoSmithKline (GSK)
GlaxoSmithKline Biologicals
Goodwin Biotechnology
Government Pharmaceutical Organisation
Green Cross
Haiwang Interlong
Halfkine Bio-Pharmac
Health Canada
Henan Puxin Bio-engineering Co.
HollisterStier
Hospira
Hualan Biological Engineering
Human Biologicals Institute
IDT Biologika
Indian Immunologicals
Innogenetics Biologicals
Instituto Fundaco Butantan
Intercell
International Federation of Pharmaceutical Manufacturers and Association (IFPMA)
Jiangsu Yanshen Biological Technology Co.
Korean FDA
Kuhner
Kunming Institute of Medical Biology
Lanzhou Institute of Biological Products
LG Life Sciences
Livzon Pharmaceutical Biotech Co.
Medicago
MedImmune
Merck & Co.
Meridian Life Science
Millipore
Mitsubishi Tanabe
Mogam Biotechnology Research Institute
Nanjing Dalu Dekang Biotech Co.
National Health Service (UK NHS)
National Institute of Allergy and Infectious Diseases
National Institutes of Health (US NIH)
National Institute of Vaccines and Biological Substances
National Vaccine & Serum Institute (NVSI)
NCPC GeneTech Biotech Dev. Co.
Novartis
Novartis Vaccines and Diagnostics Division
Novavax
Pall Life Sciences
Panacea Biotech Limited
Pan American Health Organization (PAHO)
Pfenex
Pfizer
Pfizer Vaccines
PharmAthene
Phillip Morris International
Pierre-Guerin Biolafitte
Protein Sciences Corporation (PSC)
Queen Saovabha Memorial Institute
Razi Vaccine and Serum Research Institute
Research Triangle Park
Sanofi
Sanofi Pasteur
Sartorius Stedium
Serum Institute of India
Shanghai Fudan-Yueda Biotech Co.
Shanghai Institute of Biological Products
Shanghai Institutes for Biological Sciences
Shantha Biotechnics
Shanxi Institute of Biological Products
Shenyang Baiao Biotech Co.
Shenzhen Neptunus Interlong Biotech Co.
Sinovac Biotech
Solvay
SynCo Bio Partners
Takeda
The Biovac Institute
Thermo Scientific
UNICEF
US Federal Government
Vabiotech
Vivalis
Wockhardt
Wuhan Institute of Biological Products
World Health Organization (WHO)
Wyeth (now part of Pfizer)
Wyeth Vaccines
Xcellerex
Xiamen Innovax Biotech Co.
Yunnan Wosen Biotechnology Co.
Zhejiang Pukang Biotechnology Co.
Zhejiang Tianyuan Bio-pharma Co.
Zhejiang Tianyuan Bio-Pharmaceutical Co.
Zydus Cadila 

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close